FY2025 · ended Dec 31, 2025 · Revenue $268.77M, +170.4% YoY · Filed Mar 17, 2026
Vireo Growth Inc. (VREOF) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $268.8 million and a net loss of $68.1 million. Free cash flow was -$24.6 million. As of Jun 30, 2026 it held $115.8 million in cash and investments and $163.4 million in total debt.
Revenue (TTM)
$511.67M
+316.7% vs year-ago TTM
Net income (TTM)
$-67.11M
-59.7% vs year-ago TTM
Operating cash flow (TTM)
$26.21M
+252.1% vs year-ago TTM
Free cash flow (TTM)
$-116.31M
-292.4% vs year-ago TTM
EPS (TTM)
$-0.09
+74.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
—
Net cash
$-47.60M
as of Jun 30, 2026
Operating margin
0.3%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VREOF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Minneapolis, MN
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1771706
- Former names
- Goodness Growth Holdings, Inc. (until Jun 24, 2024); Vireo Health International, Inc. (until May 14, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $268.8M | $99.4M | $88.1M | $74.6M | $54.4M |
| Operating income | -$1.0M | $13.6M | $10.6M | -$6.9M | -$20.5M |
| Net income | -$68.1M | -$28.0M | -$25.5M | -$42.5M | -$33.7M |
| Diluted EPS | -$0.09 | -$0.16 | -$0.19 | -$0.33 | -$0.27 |
| Operating cash flow | $3.7M | -$10.2M | -$965,906 | -$18.1M | -$30.5M |
| Free cash flow | -$24.6M | -$21.9M | -$5.9M | -$23.6M | -$48.6M |
| Total assets | $817.2M | $278.9M | $183.3M | $159.2M | $167.0M |
| Total liabilities | $509.7M | $223.3M | $199.3M | $155.7M | $124.0M |
| Stockholders' equity | $307.4M | $55.6M | -$16.0M | $3.4M | $43.0M |
| Cash and investments | $109.3M | $91.6M | $16.0M | $15.1M | $15.2M |
| Total debt | — | — | — | $58.0M | $27.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Agreement ended, New debt, Regulation FD disclosure
|
Oct 8, 2026 | Oct 2, 2026 |
| 8-K |
Current report
Acquisition or sale of assets, Unregistered share sale, Regulation FD disclosure
|
Aug 26, 2026 | Aug 21, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 18, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, New debt, Unregistered share sale, Regulation FD disclosure
|
Aug 13, 2026 | Aug 7, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
All 362 Vireo Growth Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.